Omontys Side Effects
Generic name: peginesatide
Medically reviewed by Drugs.com. Last updated on Dec 30, 2021.
Note: This document contains side effect information about peginesatide. Some of the dosage forms listed on this page may not apply to the brand name Omontys.
Applies to peginesatide: injectable solution
General side effects have included pyrexia (12.2%).[Ref]
Immunologic side effects have included the development of peginesatide (the active ingredient contained in Omontys) specific antibodies (1.2%).[Ref]
Other side effects have included arteriovenous fistula site complication (16.1%).[Ref]
Hypersensitivity side effects have included postmarketing reports of serious allergic reactions including fatal reactions (0.02%).
More about Omontys (peginesatide)
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Drug class: recombinant human erythropoietins
- FDA approval history
Related treatment guides
1. "Product Information. Omontys (peginesatide)." Takeda Pharmaceuticals America (2012):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.